Executive readout · one minute
Webcast research workspace
Read the call alongside every captured source. Transcript, audio stay in one workspace.
Substantial doubt about the company's ability to continue as a going concern.
“If we are unable to raise additional capital when needed, that could raise substantial doubt about our ability to continue as a going concern.”View the 10-Q filed Nov 4, 2026
Conference · 2026-11-18
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Executive readout · one minute
Read the call alongside every captured source. Transcript, audio stay in one workspace.
Research coverage
2 live sources
Switch sources without leaving this page or losing your listening position.
Open the source you need; every reader stays inside this workspace.
Perfect. All righty. Thanks so much for joining us, day three of our health care conference. My name is Akash Jawari. I head our pharma and biotech research efforts internally within Jefferies. I have the pleasure of hosting the DeMora management team, and I'm really looking forward to it. Why don't I hand it off to you, Jennifer, for some opening remarks, and we'll get to it.
Yeah, so first of all, I'm Jen Jarrett. I'm the CEO here of DeMora, and this is Sherwin Sitarzadeh, who's the COO, and this is actually the first time I've ever been to the London General Conference. I've been hearing about this for many, many years, so I'm very excited to be here, and actually, it's exceeded all of my expectations in terms of crowds and everything else, but no, but it's been a great day, so thank you for having us. So, Domora is a Fairmont company. I'm sure a lot of you guys are familiar with Fairmont companies, and like a lot of the other Fairmont companies, we were founded to develop molecules that came from the Paragon antibody platform. So all of our molecules today came from Paragon. I think Paragon has established a very well-deserved reputation for creating best-in-class antibodies, and we believe the antibodies in our portfolio are best-in-class. The antibodies that we're developing all target something called mutant CalR. Mutant CalR is a key driver mutation that's found in about one-third of patients with two different types of myeloproliferative neoplasms. So that's essential thrombocytemia and myelofibrosis. If you were to add up the number of patients in the U.S. that have that mutation, it's about 45,000 patients just in the U.S. So very big patient population. You were to apply kind of typical pricing for an NPN drug, and the market opportunity is well north of $10 billion in the U.S. alone. This class of therapies is the first targeted therapy that addresses a key underlying driver of disease in MPNs, which is why there's so much excitement around this class of therapies. Our molecule, DMR001, is our most advanced molecule. It is similar to another antibody that's in development called 989, which is a molecule that Insight's developing. They're only about two years ahead of us. So it's similar to that molecule in two ways. First of all, like the Insight molecule, it's FC Null. The second similarity is it targets the same epitope, and so the reasons why we wanted to preserve those two things in our molecule is that Insight's molecule has a very, very good safety and tolerability profile, so we wanted to replicate that. There's two key differences with our molecule, though. The first key difference is that we have a much better PK profile in half-life, so as a result, we expect to be able to administer our drug every four weeks by subcutaneous administration. That compares to 989, which is currently being dosed every two weeks by IV, and then the second major difference with our molecule is that, based on our preclinical data, it appears like it'll be very active against the type 2 mutation, so these patients that have the Keller mutation can be classified either as type 1 or type 2. The market's probably split about 50-50 between those two patient populations, and if you look at the 999 data, the data looks really good in type 1, but they're seeing much less activity against patients that have the type 2 mutation. And so based on the preclinical data that we've generated, we believe that we're getting much better potency against the type 2 mutation, and so our drug should work better in the type 2 patient population. So we're now full steam ahead with DMR-001 into our first clinical studies. This is a Phase I, 1B study. that we initiated just a little while ago. It's now open in Australia and the U.S. It is a pretty classic dose escalation expansion study. One thing that I'd point out, though, that I think is special about the study is we're able to start at a relatively high dose. Just given the fact that this is FCNOL, we target the same epitope as InSight, so we were able to leverage all of the safety and tolerability data that they have generated to convince regulatory agencies that we should be able to start at this relatively high dose. So we're starting at 100 MIGs every four weeks. We do believe that will be an active dose, which is always good, and it also limits the number of dose escalation cohorts that we'll likely need to do before we start our expansion cohorts. So I'll stop there and...
No, that's excellent. Thanks so much.
I probably covered everything.
I wish it was that simple. But I will say, actually, there is an element... It's very easy to understand the story. And I think that's why we've seen interest from Insight. We've seen interest even from, you know, Lilly very recently. So I think that is actually very true. And so, you know, one of the things I would love to get your take on. Why do you feel like there's so much interest in the CalR space? Because I think, you know, and I'm sure you had this question kind of two years ago. Well, this doesn't seem like that's that many patients, and, you know, MF and ET, usually there's a long path to development, but that's really not been the case when we think about strategically what's occurring. So what does your team see that's special about CalR, and how is that kind of getting reflected externally as well?
Yeah, so very good question. You know, so first of all, just starting with NPNs more broadly, and I did not appreciate this to your point until I got to DeMora, but there's just a lot of interest in NPNs, period. Most companies have built out an NPN capability by buying things, so Pfizer, not Pfizer, Bristol, Merck. Novartis, Lilly have all bought programs that got them into the NPN space, and what's attractive about the NPN space is, first of all, it is a pretty large patient population. You know, you do get premium pricing for these types of drugs. You get oncology-like drug pricing. The studies are actually, like, pretty small and inexpensive, particularly relative to, like, solid tumor studies, and these patients live much longer, honestly, you know, than, sadly, like, a lot of solid tumors and even hematological cancer, so the expectation is that these patients can be on We've been on treatment for many years. Interestingly, though, that doesn't really happen in practice with the JAK inhibitors. And so when you looked at the phase three study that was done with Insights JAK inhibitor, which was the first JAK inhibitor that was approved, ruxolitinib, patients were on treatment for about three years on average. So that's something that obviously got people excited about that class of drugs, because if patients were on treatment for three years at, you know, $250, whatever, $1,000 a year pricing, like, that's a pretty good MPV. In practice, though, what we hear is that patients are only on treatment for typically one year. And at that point, they just start to develop cytopenias and anemias, and they really just can't stay on treatment. They can't tolerate the treatment anymore, so they come off. RUX also does not address the underlying driver of disease. So RUX is pretty good at alleviating symptoms, reducing spleen size, but it does not address the underlying driver of disease, and it does not slow the progression of disease. And that's what these patients, like, fear the most. It's just their bone marrow. In the case of myelofibrosis patients, becoming more and more fibrotic. In the case of ET patients, they worry about their symptoms getting worse and worse, and they worry about their disease progressing to myelofibrosis. And ET is also a very similar story. Actually, the treatment options are even worse, and so hydrea is the most commonly used treatment option, which is basically like a mild form of chemotherapy. So you get, like, you know, all the same side effects you expect with chemotherapy. So again, patients do not stay on hydrea for extended periods of time. So it's gotten people excited about... The mutant killer antibody class is that you are addressing the key driver of disease in these patients, and it's a very safe and well-tolerated drug. It is so specific for this target. That's something that Insight has shown. It's something that we've shown in our preclinical data, and we are seeing, like, very, very good activity, particularly in ET. The MF data has also looked very robust. We'll see more MF data at ASH, but, like, when people look at the activity that they're seeing, like, in type 1 patients, With the T, you're getting an 80%-plus complete hematological response rate, which is pretty incredible. So that's what's gotten people very excited about this class of drugs.
Now, I think there's an element of... And we're seeing this a lot in healthcare. People can have similar assets. It's really, how do you, I'll even use the word ruthlessly, but how do you definitively think about clinical development in a way that it just shuts the door for people who might be behind you? And you do have a lead when you think about a molecule that can work in type 1 and type 2. But now you'll also compete against companies with a lot of, you know, they have GLP-1 money, as you'll often hear. But I feel like your team's really learned a lot from the INSIGHT data over the last year. What are those learnings that you're applying to your clinical development program, and how does it contrast to what INSIGHT's really going for for both ET and MF?
If you want to.
Yeah, so the first thing that we've learned is just the level of interest at the physician and patient level for therapies that are going to have this disease-modifying potential. So we started out understanding what the profile for 989 looked like, laying out the argument for DMR001 and how it's differentiated from its preclinical profile and how we expect that to translate into the clinic. And sharing that story with physicians, we just see the amount of interest that they have in participating in the DMR-001 study. This really started out as a clinical development program that had some sort of finite boundaries around the size of a program we thought we would embark on. And as we've talked to more and more physicians and patients, just the amount of interest has led us to really expand this study to be a global phase one study across a number of sites geographically That is going to allow us to go quickly. The other thing that we've learned is mutant CalR patients know that they're mutant CalR patients, so they advocate for access to better treatment options in a way that I think in a lot of other disease areas you don't see that. And so the interest that we get from patients even reaching out to us or through their physicians, that when is DMR-001 going to be open at my site that I can have access to this as well? And the reason for that is that they understand that with the great data that Insight has put out, the limitations that it does have and the convenience barriers of the every two-week IV infusion, the lack of similar potency on the type 2 mutation, which is a sizable proportion of the population, as you said. So this sort of unmet need is becoming clearer to the broader community and where DMR-001 can really fill that. So we're using those as a means to really set up this program to go quickly, to go broadly, to generate the data we need to pivot quickly to phase three.
Understood. Now, you know, I think one of the other things that I know your team is looking at and I know we're also looking at is really, you know, regulatory feedback that Insight's gotten about kind of endpoint selection in a second-line setting, but then I think the other question becomes in a first-line setting as well. Now, what's your kind of view? Let's say that we're in a world where what the second line endpoint is, where there is an acknowledgement of anemia benefit, and that is a secondary endpoint, but it's not necessarily a dual primary endpoint. How does that change your regulatory development path in front-line and second-line MF, or does it not change it either way? Because in the end of the day, by having it even as a secondary endpoint, it acknowledges the fact that the FDA is taking that into account, right? Like, are we overthinking the importance of this being a primary versus a secondary endpoint here?
And you do mean DAF?
Yeah.
You know, one thing to say, like, VAF is what, I know you know, what the KOL community has really been advocating for. Like, they really feel like VAF is your evidence of disease modification because it shows you're eradicating the mutant clone, and therefore, like, the disease is going away and you're really stopping the progression of the disease. So that's why I do think, like, if you have it as a secondary endpoint and it's on your label, I do think that's really important from a commercialization perspective because I think it just highlights It's just the importance of that class of therapies, and I think will be very meaningful to the clinicians that are prescribing that therapy, as well as payers. So I do think, like, having VAF, even if it's just as a secondary endpoint, is really important. And one thing that's interesting, like, in ET, Insight has said that the FDA was actually the one that suggested that they include VAF as a secondary endpoint. So the FDA is, I think, starting to recognize the importance, even if, you know, the... In MF, they're, you know, clearly not quite there, but I do think KOL community is going to continue to push to figure out, like, how VAF can get incorporated as an endpoint and how you maybe start to get away from the symptom score as a key endpoint.
And, but does that change your trial design or your assumption for kind of first line or, no, I guess the point is, because we'll often get this with investors, you know, the more typical TSS 50 endpoints that we'll see, is your team confident that, you know, there's a place even with that metric alone, whether it's in monotherapy and in combo with Cal Army?
Yeah, I think, and I'll answer your question in a second, but I think we also have to view this in terms of what is necessary for demonstration of an approvable data set from a regulatory standpoint versus how a product ultimately gets used based on the totality of evidence there. And the endpoints we currently have are for agents that don't have disease-modifying potential. They were designed for the attributes of the drug that demonstrates improvement on those types of endpoints, like symptoms. Whereas when you have something like Immun-Cal-R, disease-modifying directed therapy, it's going to take time for the regulatory science to catch up with the evolving clinical science to a place where we can actually then employ those endpoints for regulatory decision-making. That's not to say that the broader community is failing to understand the benefit that targeted therapy is going to bring for patients. Now, how do you incorporate that into your development program? I'm very happy that Insight is continuing to push with the volume of data that they've been generating to have that discussion with the FDA to push them to evolve beyond the classic TSS SVR endpoints. In fact, there was an international working group of MPNs that was held in D.C. about a month or so ago between industry, FDA officials, and KOLs, and the amount of interest and vocalness that the KOLs were presenting to FDA, the importance of moving towards these VAF, these anemia benefits, and really trying to move the needle away from TSS as a primary endpoint in these patients. And the way that they use VAF in order to even treat their patients and understand if their patients are benefiting or not benefiting from a therapy. So I think this is just the evolution that is going to take a little bit of time, and Insight will be leading that effort. By the time it's our turn to have those similar conversations, the FDA's thinking will have evolved to a point where perhaps we have a better opportunity to move that.
Kind of a bridge to this, you know, it's interesting. We focus so much about insights discussion with CalR, but I think there's an equally instructive case study with GSK and MoMA, right? Like, I mean, first of all, that's, A, a recognition that the FDA, that's a lower SVR rate than Jackify. They still found a path to get onto the market and frontline, and A, that's an acknowledgment that anemia benefits are critically important, but B, that was a different trial design than what we've seen with some of the jacks that have come recently. So how much have you learned from Momo's frontline development, I'm going to call it that, that you might be able to apply with your program?
So I think, you know, when you look at, and we've talked to Ana Phoebe a lot about this, I mean, if you look at all the MF studies that have been done, I'd say what's probably been used the most is a sole primary of SVR and then a key secondary of TSS-50. But as you pointed out, like, there's also been some variation, including what JSK did or CR did with mamalotinib. So I think that does show, like, there's flexibility, and so, you know, we'll continue to figure out, like, what we think are the best endpoints for this class of therapies, but there's a lot of different opportunities and options, I think, out there, and so, you know, we will figure out what's best for us. I do think, like, if you look at the SVR35 data that's been presented so far for 989, and we'll see more data, obviously, at ASH, it feels like either in the second-line setting or front-line setting in the type 1 patient population, like, they should be RUX or whatever the control arm is pretty meaningfully. And, you know, especially since they said that patients that have the color mutation that get rexolitinib do meaningfully worse versus the non-mute color patients, which tells you, like, you know, the 40% or 30% comfort, like, is not the real number. It's really more like 20%. So I also think, like, if you did end up with SVR 35 and TSS 50, I still think you have, like, a very good shot to succeed. But there still may be better endpoints that really capture the benefits of this class of therapies, like, anemia benefit to your point.
Very much agree on both fronts. Now, you know, Lilly acquired a company that is in a similar area of development as you. Uh, behind, though. Um, but, you know, it's interesting. We were kind of thinking about this internally when we were looking at it. Lily has a selective JAK1, JAK2. It's shown interesting data, but I think your team's been very insistent. I think rightfully so that there are distinct places for JAK inhibitors and CalR. And, you know, we were kind of thinking about this, too. That Jack Selective that they got from Ajax, really nice response rates, but you still had a lot of anemia, and you still had team talks. So, and your guess is as good as ours. Do you feel like the acquisition from Lilly is a combo? You know, like, it's a sign that actually combination approach. Is really the right place? Or is it actually a sign that, no, it's a recognition that CalR in of itself is a distinct market in MF&ET?
And you're, again, the guest. I mean, I do think they have been interested in immune-cal-R. I think they've been vocal about that. I do think they were also interested in combining immune-cal-R antibody with their JAK inhibitor because if you remember in the data that they presented at EHA, you know, they had very good activity. If you look at VAF, which was the only data where they really broke out efficacy by mutation, they saw very good VAF reductions in patients with JAK2V617F, but almost no VAF reduction in patients with immune-cal-R. So, again, like, makes that point that, you know, these selective JAK inhibitors don't perform as well in a mutant calorie patient or do as much as a mutant calorie patient. But your point, I think it's a bit of both. I think they like this target as do, I think, a lot of people, and I do think they wanted something to combine with the drug that they got from Ajax. I do also think, and this is something else we'll see at ASH, that there's still some question about whether a combination or monotherapy strategy is the right strategy for a mutant calorie antibody in the front line. And I think there's a lot of different views. I do think, like, probably the predominant view is that monotherapy is probably better because so far the combination data seems to show that there's not a ton of added efficacy when you add RUCs, but you are bringing additional toxicity. And so, again, you know, we'll see what the latest data shows, but, you know, I think if Lilley does go in the direction of, like, combining the Ajax molecule with the Calatrix molecule, that's just, like, something to keep an eye on.
I think, can you walk a bit about, you have a drug that works in type 1 and type 2, and what does that allow you from a powering perspective, a trial design perspective, that not only, let's say, makes your clinical path to market simpler, but actually maybe allows more certainty for getting to market quickly? Like, how does the agency think about this, too?
Yeah, I mean, the target product profile we're pursuing for 001 is one that has a single dose for regardless if it's a type 1 patient or type 2 patient, ideally regardless if it's an ET patient or an MF patient. And so what that affords you is to sort of not go through the complexities that 989's phase 3 study designs have had to do, which in ET has a single titration step up for patients based on their platelet counts at day 15. So everybody starts at 750 milligrams every two weeks, goes up to 2,500 milligrams as a means to capture the non-type 1 patients to give them an opportunity to have a better response rate. So you're essentially... Ending up with four different patient populations at the end that you're going to have to decide how you're going to statistically test for between two populations and two dose levels. On the myelofibrosis second-line study, they're enrolling all patients but have designed the study to statistically test for type 1 patients first, given their lower activity in the non-type 1 population or the type 2 population. So in the product profile we're pursuing, it just simplifies a lot of those things. Your statistics are based on a response rate estimate at a dose. It just becomes that much simpler and potentially smaller studies to demonstrate the phase three. Efficacy and safety.
Understood. And when you think about combo versus monotherapy, you mentioned what we've seen in MF. Can you talk a bit about ET as well? What do you think will ultimately be the paradigm in a frontline setting? Do you think combination is even the right approach here, or is it really going to be about monotherapy Cal-R?
Yeah, I think in ET in particular, especially since there's not like an obvious combination partner, and I think everyone wants to get away from hydrea versus figure out like how do you just go on top of hydrea. So yeah, and when you look at like the type one monotherapy data, like it looks very strong. You know, it's type two where like you're not seeing the activity that you'd ideally like to see. So it also just, you know, when you look at the data, it doesn't seem to suggest you need to add something to mutant calorie antibody to get the activity.
Understood. Now, I'd love to hear a take, too. As you get longer duration on treatment, right? And so we're looking at some of these anemia endpoints, but we think about them maybe statically. I don't think we're thinking about it from a long-term perspective. Do you have a view on what could really, you know, with CalR, potent CalR, sustained inhibition over a period of time, deliver in terms of functional outcomes for some of these patients that we're not really talking about right now?
Yeah, I think, um... When we talk about our base case TPP, we're assuming for now our type 1 activity looks similar to 989, but I do think there's some possibility that because we're getting much better target coverage, like when you look at their PK curve, and they've never disclosed their PK curves in humans, so this is just based on non-human primate data. You know, it's a little bit unclear if they're really covering the target for the full 14-day period of their dosing interval. So with our drug, we do think we're going to get complete coverage, more than complete coverage, like, over the course of the dosing interval. So you do wonder, like, will that translate into better efficacy, like, in type 1 MF, where, you know, maybe they're still leaving a little bit of efficacy on the table relative. Like, ET, it feels like, you know, they're getting a lot out of this mechanism in, like, a type 1 ET patient. But, you know, type 1 MF patients, like, maybe there's still a little bit of efficacy that's left off the table. So, you know, at least we'll... We'll run the experiment and see if, like, you know, covering the target better over a longer period of time, does that result in better efficacy in those type 1 MF patients?
Understood. Maybe just lastly, I think not just you, but other players in the space have talked about, hey, you know, we look at momolotinib, anemia benefit might be an interesting combination partner. But I know your team is looking at the entire gamut, and even if you look at your own portfolio, you're looking at CalR and you're cutting it three different ways. Are there other emerging data sets, other interesting biology, which you feel like would be potentially synergistic with CalR beyond just simply JAK inhibition that you're really excited about?
No. Honestly, no. There's really not a lot going on in this space as part of it. The other class of drugs is the LSD-1 inhibitors, which Merck is developing, and ET, but it's not a great tolerability profile, so I think there's a lot of questions about how. And we'll utilize that class of drugs that's going to be an ET. And again, like, we really love the safety and tolerability profile of 989 and what we expect our drug to have. So we don't love the idea of, like, combining with something that then diminishes that safety and tolerability profile. Like, you know, I was asking when, we're talking to one KOL last week, and he said he'd just been asked by someone what side effects he sees in patients that are on 989, because he's had a lot of patients on 989. He said, I literally could not think of one thing, which is really unusual. I mean, this is like a heme cancer drug, and, you know, the fact that you're really not seeing anything that stands out from a side effect profile. So we do want to really preserve that, and that's what makes, like, any combination. Challenging.
Understood. And I do think that's important. It's, again, I think your team has the opportunity to really shut the door.
Yeah, and like in ET, like, you know, you want these patients, I mean, these patients live for 23 years, like, you want these patients to be on treatment for as long as possible. And the other thing that tends to happen with combinations is that it's just harder, especially as you see more toxic, keep patients on both treatments. And so, you know, patients start to discontinue one treatment or both treatments because of that additional toxicity. So, then you're losing efficacy. So, that's just the other challenge when you're...
Understood. I didn't expect that answer, but I appreciate it.
But we do like the idea of combining jacks, to be clear. And there's, you know, some jacks out there that we like and whatever. So I'll end there.
On that note, hey, thank you so much. I really do appreciate it.
0:00 to 26:21 · One card per analyst, follow-ups included. Each plays from its start, and the one being answered is marked.
Perfect. All righty. Thanks so much for joining us, day three of our health care conference. My name is Akash Jawari. I head our pharma and biotech research efforts internally within Jefferies. I have the pleasure of hosting the DeMora management team, and I'm really looking forward to it. Why don't I hand it off to…
Jennifer Jarrett: Yeah, so first of all, I'm Jen Jarrett. I'm the CEO here of DeMora, and this is Sherwin Sitarzadeh, who's the COO, and this is actually the first time I've ever been to the London General Conference. I've been hearing about this for many, many years, so I'm…
Also speaking: Sherwin Sattarzadeh